A detailed history of Bank Of America Corp transactions in Verona Pharma PLC stock. As of the latest transaction made, Bank Of America Corp holds 504,049 shares of VRNA stock, worth $22.7 Million. This represents 0.0% of its overall portfolio holdings.

Number of Shares
504,049
Previous 611,018 17.51%
Holding current value
$22.7 Million
Previous $8.84 Million 64.13%
% of portfolio
0.0%
Previous 0.0%

Shares

13 transactions
Quarter Operation Price Per share shares change shares Held SEC Form
Q3 2024

Nov 14, 2024

SELL
$15.46 - $30.16 $1.65 Million - $3.23 Million
-106,969 Reduced 17.51%
504,049 $14.5 Million
Q2 2024

Aug 14, 2024

BUY
$11.48 - $17.02 $5.54 Million - $8.21 Million
482,619 Added 375.87%
611,018 $8.84 Million
Q1 2024

May 15, 2024

BUY
$15.3 - $20.24 $679,518 - $898,919
44,413 Added 52.88%
128,399 $2.07 Million
Q4 2023

Feb 14, 2024

BUY
$11.94 - $20.47 $253,832 - $435,171
21,259 Added 33.89%
83,986 $1.67 Million
Q2 2023

Aug 14, 2023

SELL
$19.41 - $23.43 $288,781 - $348,591
-14,878 Reduced 19.17%
62,727 $1.33 Million
Q1 2023

May 12, 2023

BUY
$18.06 - $25.27 $662,910 - $927,560
36,706 Added 89.75%
77,605 $1.56 Million
Q4 2022

Feb 10, 2023

BUY
$9.84 - $26.13 $388,866 - $1.03 Million
39,519 Added 2863.7%
40,899 $1.07 Million
Q3 2022

Nov 14, 2022

SELL
$4.14 - $13.59 $1,229 - $4,036
-297 Reduced 17.71%
1,380 $14,000
Q2 2022

Aug 12, 2022

BUY
$3.55 - $5.06 $3,841 - $5,474
1,082 Added 181.85%
1,677 $7,000
Q1 2022

May 16, 2022

SELL
$4.82 - $6.98 $1,913 - $2,771
-397 Reduced 40.02%
595 $3,000
Q4 2021

Feb 08, 2022

SELL
$3.91 - $7.08 $39,404 - $71,352
-10,078 Reduced 91.04%
992 $7,000
Q3 2021

Nov 15, 2021

BUY
$5.29 - $6.35 $40,812 - $48,990
7,715 Added 229.96%
11,070 $60,000
Q2 2021

Sep 13, 2021

BUY
$5.72 - $9.09 $19,190 - $30,496
3,355 New
3,355 $22,000

Others Institutions Holding VRNA

About Verona Pharma plc


  • Ticker VRNA
  • Exchange NASDAQ
  • Sector Healthcare
  • Industry Biotechnology
  • Shares Outstandng 60,954,200
  • Market Cap $2.75B
  • Description
  • Verona Pharma plc, a clinical stage biopharmaceutical company, focuses on development and commercialization of therapies for the treatment of respiratory diseases with unmet medical needs. The company's product candidate is ensifentrine, an inhaled and dual inhibitor of the phosphodiesterase (PDE) 3 and PDE4 enzymes that acts as both a bronchodi...
More about VRNA
Track This Portfolio

Track Bank Of America Corp Portfolio

Follow Bank Of America Corp and customize your updates to receive the information that matters most to you.

Portfolio Update

Get notified when there are updates to the investment portfolio of Bank Of America Corp , based on Form 13F filings with the SEC.

News

Stay updated on Bank Of America Corp with notifications on news.